Giovanni Iodice

957 total citations
19 papers, 499 citations indexed

About

Giovanni Iodice is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Giovanni Iodice has authored 19 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Giovanni Iodice's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and HER2/EGFR in Cancer Research (5 papers). Giovanni Iodice is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and HER2/EGFR in Cancer Research (5 papers). Giovanni Iodice collaborates with scholars based in Italy, Malaysia and United Kingdom. Giovanni Iodice's co-authors include Michelino De Laurentiis, Gerardo Botti, Fabio Lucidi, Antonio Giordano, Fabio Alivernini, Luigi Gallo, C Milanese, Giovan Giacomo Giordano, Giuseppe De Pietro and Paola Indovina and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and British Journal of Cancer.

In The Last Decade

Giovanni Iodice

18 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giovanni Iodice Italy 9 273 141 135 60 55 19 499
Xinni Song Canada 13 252 0.9× 61 0.4× 144 1.1× 17 0.3× 18 0.3× 38 459
Yiola Marcou Cyprus 11 197 0.7× 109 0.8× 75 0.6× 35 0.6× 17 0.3× 23 536
Michael G. McCusker United States 10 239 0.9× 92 0.7× 200 1.5× 29 0.5× 28 0.5× 20 553
Clizia Zichi Italy 12 140 0.5× 47 0.3× 140 1.0× 105 1.8× 20 0.4× 38 432
César Cabello Brazil 11 196 0.7× 82 0.6× 58 0.4× 35 0.6× 10 0.2× 33 392
Michal Rajski Switzerland 8 112 0.4× 184 1.3× 85 0.6× 21 0.3× 14 0.3× 8 619
Colleen McGuire United States 10 270 1.0× 56 0.4× 162 1.2× 83 1.4× 6 0.1× 16 801
Ermanno Rondini Italy 10 178 0.7× 137 1.0× 127 0.9× 13 0.2× 7 0.1× 32 394
Paola Sgandurra Italy 10 226 0.8× 118 0.8× 63 0.5× 150 2.5× 12 0.2× 13 488
LI Guo-ping China 9 113 0.4× 82 0.6× 65 0.5× 96 1.6× 15 0.3× 12 593

Countries citing papers authored by Giovanni Iodice

Since Specialization
Citations

This map shows the geographic impact of Giovanni Iodice's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Iodice with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Iodice more than expected).

Fields of papers citing papers by Giovanni Iodice

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giovanni Iodice. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Iodice. The network helps show where Giovanni Iodice may publish in the future.

Co-authorship network of co-authors of Giovanni Iodice

This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Iodice. A scholar is included among the top collaborators of Giovanni Iodice based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Iodice. Giovanni Iodice is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chirico, Andrea, Paola Indovina, C Milanese, et al.. (2020). Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy. Journal of Cellular Physiology. 235(6). 5353–5362. 152 indexed citations
2.
Piezzo, Michela, Paolo Chiodini, Stefania Cocco, et al.. (2020). Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 21(17). 6400–6400. 79 indexed citations
3.
4.
Esposito, Emanuela, Maurizio Di Bonito, Giovanni Iodice, et al.. (2019). Intracystic papillary breast carcinoma with DCIS in a man: a case report. Translational Cancer Research. 8(S5). S445–S448.
5.
Avallone, Antonio, Paolo Delrio, Biagio Pecori, et al.. (2010). Oxaliplatin Plus Dual Inhibition of Thymidilate Synthase During Preoperative Pelvic Radiotherapy for Locally Advanced Rectal Carcinoma: Long-Term Outcome. International Journal of Radiation Oncology*Biology*Physics. 79(3). 670–676. 23 indexed citations
6.
Comella, P., Massimo Rinaldo, Giovanni Iodice, et al.. (2009). Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer. Annals of Oncology. 20(7). 1185–1192. 71 indexed citations
8.
Frasci, G., P. Comella, R. Thomas, et al.. (2008). Weekly cisplatin-epirubicin-paclitaxel with G-CSF support in ER-negative large operable breast cancer. The NCI of Naples’ nine-year experience. Journal of Clinical Oncology. 26(15_suppl). 577–577. 4 indexed citations
11.
Frasci, G., P. Comella, R. Thomas, et al.. (2005). A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study. Journal of Clinical Oncology. 23(16_suppl). 566–566. 4 indexed citations
12.
Frasci, G., P. Comella, Andrea Siani, et al.. (2005). Weekly cisplatin-epirubicin-paclitaxel with G-CSF support (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Final results of the 9908 SICOG trial. Journal of Clinical Oncology. 23(16_suppl). 580–580. 3 indexed citations
13.
Tartarone, Alfredo, Giuseppina Gallucci, Giovanni Iodice, et al.. (2004). Linezolid-induced bradycardia: a case report. International Journal of Antimicrobial Agents. 23(4). 412–413. 8 indexed citations
14.
D’Arena, Giovanni, Maria Luigia Vigliotti, V. Pizza, et al.. (2004). Guillain-Barré Syndrome Complicating Mobilization Therapy in a Case of B-cell Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 45(7). 1489–1490. 6 indexed citations
15.
Tartarone, Alfredo, Gianpiero Romano, Rocco Galasso, et al.. (2003). Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. Bone Marrow Transplantation. 31(7). 525–530. 10 indexed citations
16.
Giardiello, Cristiano, et al.. (2001). [Diagnosis, therapy, and follow up in synchronous colorectal cancer of the colon].. PubMed. 22(4). 122–4. 1 indexed citations
17.
Colao, Annamaria, A. Balzano, Diego Ferone, et al.. (1997). Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clinical Endocrinology. 47(1). 23–28. 64 indexed citations
18.
Battista, Claudia, N. Panza, Bruno Chiurazzi, et al.. (1993). Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM). Biomedicine & Pharmacotherapy. 47(4). 145–154. 1 indexed citations
19.
Vacca, Angelo, et al.. (1985). Cyclic lysozyme administration as a tool for immunopotentiation in patients with multiple myeloma.. PubMed. 4(2). 147–55. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026